An analysis of insurance claims data found that if GLP-1 drugs used for weight loss and diabetes were priced below $350 per month, payers such as employers and plan sponsors would achieve net savings from reduced use of related medical services.
This analysis was conducted by CVS Health based on claims data from patients who recently began treatment through its insurance subsidiary Aetna.
Eli Lilly (LLY.US) sells Zepbound (tirzepatide) for obesity and Mounjaro (tirzepatide) for type 2 diabetes, while Novo Nordisk (NVO.US) sells Wegovy (semaglutide, for weight loss) and Ozempic (semaglutide, for diabetes), respectively.
The Gap Between Current Prices and the "Break-Even Point"
According to an October 2025 report from the Employee Benefit Research Institute (EBRI), employers and health plan sponsors pay an average monthly cost of between $617 and $766 for GLP-1 drugs.
At this level, drug costs cannot be offset by savings from reduced use of medical services.
Eli Lilly and Novo Nordisk currently offer GLP-1 prices ranging from $299 to $499 per month for self-pay customers, depending on dosage, which is close to but not yet broadly below the $350 threshold.
CVS Health Chief Medical Officer Amy Compton-Phillips told Reuters that she believes drugmakers can still achieve profitability even if they sell at prices below $350 per month.
The analysis will be presented on Sunday at the HLTH USA conference in Las Vegas.
Why This Analysis Deserves Attention
For employers and insurance plans, the GLP-1 ledger has always been a dilemma: the drug cost alone represents a massive expense, but if weight loss leads to fewer complications and reduced demand for hospitalization and surgery, the long-term total cost could actually be lower.
CVS's analysis effectively provides an actionable pricing coordinate of $350 per month for this debate.
This statement also comes at a critical juncture for CVS itself: the company announced just last week that it will split into two companies in the first half of 2028, with Aetna and Caremark (PBM) remaining under CVS Health while the retail pharmacy operates independently.
As a conglomerate that simultaneously controls insurance (Aetna), pharmacy benefit management (Caremark), and a pharmacy network, CVS's position on GLP-1 pricing naturally carries the implication of "buyer bargaining power."
Comments